| Zacks Company Profile for Celularity, Inc. (CELU : NSDQ) |
|
|
| |
| • Company Description |
| Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells targeting indications across cancer, infectious and degenerative diseases. Celularity Inc., formerly known as GX Acquisition Corp., is based in NEW YORK.
Number of Employees: 123 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $2.20 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 478,217 shares |
| Shares Outstanding: 23.95 (millions) |
| Market Capitalization: $52.69 (millions) |
| Beta: 0.74 |
| 52 Week High: $5.22 |
| 52 Week Low: $1.00 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
22.91% |
16.73% |
| 12 Week |
30.18% |
13.38% |
| Year To Date |
5.77% |
-1.21% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Robert J. Hariri - Chief Executive Officer and Chairman
David C. Beers - Chief Financial Officer
Dean C. Kehler - Director
Diane Parks - Director
Geoffrey Ling - Director
|
|
Peer Information
Celularity, Inc. (CORR.)
Celularity, Inc. (RSPI)
Celularity, Inc. (CGXP)
Celularity, Inc. (BGEN)
Celularity, Inc. (GTBP)
Celularity, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 151190204
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 11/06/25
|
|
Share - Related Items
Shares Outstanding: 23.95
Most Recent Split Date: 2.00 (0.10:1)
Beta: 0.74
Market Capitalization: $52.69 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 11/06/25 |
|
|
|
| |
